Econd-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC

Conditions: Hepatocellular Carcinoma Interventions: Drug: Cadonilimab+Lenvatinib Sponsors: Hui-Chuan Sun; Sun Yat-sen University; Eastern Hepatobiliary Surgery Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials